Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)

CompletedOBSERVATIONAL
Enrollment

3,234

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

January 31, 2008

Conditions
Parkinson Disease
Trial Locations (49)

Unknown

248.619.01034 Neurological Physicians of Arizona, Gilbert

248.619.01007 Mayo Clinic - Scottsdale, Scottsdale

248.619.01025 Sun Health Research Institute, Sun City

248.619.01018 Margolin Brain Institute, Fresno

248.619.01031 Pacific Neuroscience Medical Group, Inc., Oxnard

248.619.01016 San Francisco VA PD Research, Education, & Clinical Center, San Francisco

248.619.01023 The Parkinson's Institute, Sunnyvale

248.619.01021 Boehringer Ingelheim Investigational Site, Englewood

248.619.01027 Associated Neurologists, P.C., Danbury

248.619.01013 Molecular NeuroImaging, New Haven

248.619.01020 Parkinson's Disease and Movement Disorders of Boca Raton, Boca Raton

248.619.01009 University of Florida, Gainesville

248.619.01035 Emory University, Atlanta

248.619.01006 Medical College of Georgia, Augusta

248.619.01014 Northwestern University, Chicago

248.619.01001 The University of Kansas Medical Center, Kansas City

248.619.01015 John Hopkins Hospital, Baltimore

248.619.01029 Clinical Neuroscience Center, Southfield

248.619.01022 University of Minnesota, Minneapolis

248.619.01008 Robert Wood Johnson Medical School, Piscataway

248.619.01030 Parkinson's Disease and Movement Disorders Center, Albany

248.619.01036 Parkinson's Disease and Mov. Disorders Center of Long Island, Commack

248.619.01017 Weill Cornell medical College, New York

248.619.01003 Duke University Medical Center, Durham

248.619.01028 The Cleveland Clinic Foundation, Cleveland

248.619.01004 Lehigh Valley Hospital, Allentown

248.619.01010 Parkinson's Disease research, Education and Clinical Center, Philadelphia

248.619.01011 University of Pennsylvania, Philadelphia

248.619.01024 Thomas Jefferson Hospital, Philadelphia

248.619.01019 Boehringer Ingelheim Investigational Site, Pittsburgh

248.619.01012 Parkinson's Disease and Movement Disorders Center, Upland

248.619.01005 NeuroHealth, Warwick

248.619.01033 Vanderbilt University Medical Center, Nashville

248.619.01032 Neurology Spclst of Dallas, PA, Dallas

248.619.01002 Baylor College of Medicine, Houston

248.619.01026 Neurology/Southeast Parkinson's Disease, Richmond

248.619.02011 University of Calgary, Calgary

248.619.02010 The Glenrose Rehab. Hospital, Edmonton

248.619.02009 Movement Disorder Clinic, Winnipeg

248.619.02005 Health Sciences Centre, St. John's

248.619.02019 Dr. David King, Halifax

248.619.02013, Kitchener

248.619.02018 London HSC - University Hospital, London

248.619.02001 Centre for Movement Discorder, Markham

248.619.02008 Ottawa Civic Hospital, Ottawa

248.619.02016 The Toronto Western Hospital, Toronto

248.619.02003 Unite des Troubles du Mouvement, Montreal

248.619.02002 Memory and Motor Skills Disorders Clinic, Québec

248.619.02017 Royal University Hospital, Saskatoon

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT00617019 - Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study) | Biotech Hunter | Biotech Hunter